Today: 20 March 2026
Subscribe
Browse Category

CPH:ORSTED 10 August 2025 - 29 December 2025

Trump offshore wind pause sparks governors’ push for classified briefing and restart

Trump offshore wind pause sparks governors’ push for classified briefing and restart

Four Northeast governors asked Interior Secretary Doug Burgum to lift stop-work orders on five offshore wind projects and provide a classified briefing on national security concerns. The Trump administration paused the projects, citing military radar interference. Developers including Ørsted and Equinor say they are complying. At least 50 workers lost jobs at Vineyard Wind due to the halt, according to union officials.
29 December 2025
···
Record Closing Highs, GPT-5 Unleashed, and a $500 Billion Surprise – Business News Roundup (Aug 9–10, 2025)

Record Closing Highs, GPT-5 Unleashed, and a $500 Billion Surprise – Business News Roundup (Aug 9–10, 2025)

The Nasdaq Composite closed at its 18th record high of 2025. OpenAI launched GPT-5 for 700 million users, targeting a $500 billion valuation. Federal Reserve Vice Chair Michelle Bowman signaled three rate cuts likely by year-end. Nexstar Media Group entered advanced talks to acquire Tegna, sending Tegna shares up 30%.
10 August 2025
······

Stock Market Today

  • McKesson Q3 2026 Earnings Shine on Specialty and Oncology Growth
    March 20, 2026, 9:37 AM EDT. McKesson (MCK) reported a strong third quarter for fiscal 2026, posting 11% revenue growth and 13% rise in operating profit driven by specialty distribution, oncology services, and biopharma solutions. The company, with a $112.7 billion market cap, surpassed earnings estimates in four consecutive quarters, reflecting disciplined capital management and operational efficiency. Specialty pharmaceuticals, especially GLP-1 therapies, surged 26% year-over-year, fueling demand for high-margin, complex drug distribution. McKesson's oncology segment saw 57% profit growth, benefiting from acquisitions and organic expansion. While shares gained 29% over six months, outperforming the industry and S&P 500, margin pressures in the core pharmaceutical distribution segment could moderate gains. Investors should weigh McKesson's growth prospects against these structural challenges for long-term portfolio inclusion.
Go toTop